Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:35:51.871Z.
Calculation as of: 2026-10-06T16:35:51.871Z.
Quote observation: 2026-10-06T16:35:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 29544bddba9647c45f1d116a926e76fce0232fba061b4e126f75ac7ab8440d73
PE RATIO
N/A
Market Cap
$841.18M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$846.80M
PE Ratio
N/A
TTM Avg
76.88
3Y Avg
76.88
5Y Avg
76.88
Market Cap
$838.62M
PE Ratio
N/A
TTM Avg
351.06
3Y Avg
351.06
5Y Avg
351.06
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | $840.86M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $843.04M | N/A | N/A | N/A | N/A |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $841.18M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $846.80M | N/A | 76.88 | 76.88 | 76.88 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A | 351.06 | 351.06 | 351.06 |
| QuidelOrtho Corporation (QDEL)vs › | $850.70M | N/A | 151.06 | 53.96 | 49.56 |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $820.60M | N/A | N/A | N/A | N/A |
| SI-BONE, Inc. (SIBN)vs › | $866.41M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $808.58M | N/A | 197.34 | 197.34 | 197.34 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$18.69
Forward EPS (Est.)
$-2.05
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
